A new study has offered further evidence of the benefits the antiepileptic drug (AED) levetiracetam can provide for children with epilepsy.Led by Ege University in Turkey, the research aimed to assess the efficacy and safety of levetiracetam used on its own (monotherapy) in a group of children with epilepsy. Data from 351 children aged between 6 months and 18 years, who had different types of epilepsy, were included in the study.According to results published in the medical journal Seizure, retention rates for the AED three and 12 months following the commencement of treatment were 66% and 63%, respectively.At both junctures, the proportion of children experiencing a seizure reduction rate of 90% or greater was around 65%, and approximately 15% had a seizure reduction rate of between 50% and 90%.Overall, 17% of subjects showed adverse effects, with the most common being irritability, hyperactivity and drowsiness. As such, it was concluded that levetiracetam can be an effective initial monotherapy for different types of seizures and epilepsy syndromes.The study concluded: “There is still a need for well-designed trials to justify the widespread use of levetiracetam monotherapy in children with specific epilepsy syndromes.”Posted by Bob JonesClick here for more articles about anti-epileptic drugs and pregnancy risks.Click here for more articles about epilepsy in children.